Results 41 to 50 of about 7,531 (200)

Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. [PDF]

, 2016
INTRODUCTION: The influenza vaccine is less immunogenic in older than younger adults, and the duration of protection is unclear. Determining if protection persists beyond a typical seasonal epidemic is important for climates where influenza virus ...
Cook, Alex R, I-Cheng, Mark Chen, Parry, Christopher M, Wilder-Smith, Annelies, Young, Barnaby, Zhao, Xiahong   +5 more
core   +1 more source

MF59 adjuvant: the best insurance against influenza strain diversity

Expert Review of Vaccines, 2011
MF59 is a well-established, safe and potent vaccine adjuvant that has been licensed for more than 13 years for use in an influenza vaccine focused on elderly subjects (Fluad®), Novartis, Cambridge, MA, USA). Recently, MF59 was shown to be safe in a seasonal influenza vaccine for young children and was able to increase vaccine efficacy from 43 to 89%. A
Derek T, O'Hagan, Rino, Rappuoli, Ennio, De Gregorio, Theodore, Tsai, Giuseppe, Del Giudice   +4 more
openaire   +2 more sources

Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination [PDF]

Journal of Clinical Investigation, 2019
Seasonal and pandemic influenza infection remains a major public health concern worldwide. Driving robust humoral immunity has been a challenge given preexisting, often cross-reactive, immunity and in particular, poorly immunogenic avian antigens. To overcome immune barriers, the adjuvant MF59 has been used in seasonal influenza vaccines to increase ...
Carolyn M. Boudreau, Wen-Han Yu, Todd J. Suscovich, H. Keipp Talbot, Kathryn M. Edwards, Galit Alter   +5 more
openaire   +2 more sources

Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population

Human Vaccines & Immunotherapeutics, 2018
In the perspective of reaching at least 75% influenza vaccination coverage in the elderly and substantial budget constraints, Italian decision makers are facing important challenges in determining an optimal immunization strategy for this growing and ...
Stefano Capri, Marco Barbieri, Chiara de Waure, Sara Boccalini, Donatella Panatto   +4 more
doaj   +1 more source

The type of adjuvant in whole inactivated influenza a virus vaccines impacts vaccine-associated enhanced respiratory disease [PDF]

, 2018
Influenza A virus (IAV) causes a disease burden in the swine industry in the US and is a challenge to prevent due to substantial genetic and antigenic diversity of IAV that circulate in pig populations.
Gauger, P C, Lewis, N S, Lopes, S, Loving, C L, Rajão, D S, Sandbulte, M R, Souza, C K, Vincent, A L   +7 more
core   +2 more sources

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults

New England Journal of Medicine, 2021
A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous regimen using HIV-1 subtype C virus showed potent humoral and cellular responses in a phase 1-2a trial in South ...
Glenda E. Gray, Linda-Gail Bekker, Fatima Laher, Mookho Malahleha, Mary Allen, Zoe Moodie, Nicole Grunenberg, Yunda Huang, Doug Grove, Brittany Prigmore, Jia J. Kee, David Benkeser, John Hural, Craig Innes, Erica Lazarus, Graeme Meintjes, Nivashnee Naicker, Dishiki Kalonji, Maphoshane Nchabeleng, Modulakgotla Sebe, Nishanta Singh, Philip Kotze, Sheetal Kassim, Thozama Dubula, Vimla Naicker, William Brumskine, Cleon N. Ncayiya, Amy M. Ward, Nigel Garrett, Girisha Kistnasami, Zakir Gaffoor, Pearl Selepe, Philisiwe B. Makhoba, Matsontso P. Mathebula, Pamela Mda, Tania Adonis, Katlego S. Mapetla, Bontle Modibedi, Tricia Philip, Gladys Kobane, Carter Bentley, Shelly Ramirez, Simbarashe Takuva, Megan Jones, Mpho Sikhosana, Millicent Atujuna, Michele Andrasik, Nima S. Hejazi, Adrian Puren, Lubbe Wiesner, Sanjay Phogat, Carlos Diaz Granados, Marguerite Koutsoukos, Olivier Van Der Meeren, Susan W. Barnett, Niranjan Kanesa-Thasan, James G. Kublin, M. Juliana McElrath, Peter B. Gilbert, Holly Janes, Lawrence Corey   +60 more
openaire   +3 more sources

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineResearch in context

EBioMedicine, 2023
Summary: Background: The SARS-CoV-2 global pandemic has fuelled the generation of vaccines at an unprecedented pace and scale. However, many challenges remain, including: the emergence of vaccine-resistant mutant viruses, vaccine stability during ...
Georgia Deliyannis, Nicholas A. Gherardin, Chinn Yi Wong, Samantha L. Grimley, James P. Cooney, Samuel J. Redmond, Paula Ellenberg, Kathryn C. Davidson, Francesca L. Mordant, Tim Smith, Marianne Gillard, Ester Lopez, Julie McAuley, Chee Wah Tan, Jing J. Wang, Weiguang Zeng, Mason Littlejohn, Runhong Zhou, Jasper Fuk-Woo Chan, Zhi-wei Chen, Airn E. Hartwig, Richard Bowen, Jason M. Mackenzie, Elizabeth Vincan, Joseph Torresi, Katherine Kedzierska, Colin W. Pouton, Tom P. Gordon, Lin-fa Wang, Stephen J. Kent, Adam K. Wheatley, Sharon R. Lewin, Kanta Subbarao, Amy W. Chung, Marc Pellegrini, Trent Munro, Terry Nolan, Steven Rockman, David C. Jackson, Damian F.J. Purcell, Dale I. Godfrey   +40 more
doaj   +1 more source

MF59-based lipid nanocarriers for paclitaxel delivery: optimization and anticancer evaluation. [PDF]

Sci Rep
Abstract Breast cancer is the most common invasive cancer in women worldwide, necessitating innovative therapeutic strategies to enhance treatment efficacy and safety. This study focuses on the development and optimization of novel paclitaxel (PTX)-loaded nanostructured lipid carriers (NLCs) that incorporate components of MF59, an oil-in ...
Attar M, Tash Shamsabadi F, Soltani A, Joghataei MT, Khandoozi SR, Teimourian S, Shahbazi M, Erfani-Moghadam V.   +7 more
europepmc   +4 more sources

Superior efficacy of a human immunodeficiency virus vaccine combined with antiretroviral prevention in simian-human immunodeficiency virus-challenged nonhuman primates [PDF]

, 2016
International ...
Barnett, Susan W., Cope, Alethea, Dereuddre-Bosquet, Nathalie, Desjardins, Delphine, Dispinseri, Stefania, Gosse, Leslie, Le Grand, Roger, Ochsenbauer, Christina, Prague, Mélanie, Saidi, Hela, Scarlatti, Gabriella, Shattock, Robin J., Shen, Xiaoying, Silvestri, G., Thiébaut, Rodolphe, Tolazzi, Monica, Tomaras, Georgia   +16 more
core   +4 more sources

Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults

Vaccine, 2020
Evaluate whether adjuvanted quadrivalent influenza vaccine (aQIV) elicits a noninferior immune response compared with a licensed adjuvanted trivalent influenza vaccine (aTIV-1; Fluad™) and aTIV-2 containing an alternate B strain, examine whether aQIV had immunological superiority for the B strain absent from aTIV comparators, and evaluate ...
Brandon, Essink, Carlos, Fierro, Jeffrey, Rosen, Amparo L, Figueroa, Bin, Zhang, Carole, Verhoeven, Jonathan, Edelman, Igor, Smolenov   +7 more
openaire   +2 more sources